Skip to main content
ARVN
NASDAQ Life Sciences

Arvinas Reports Significantly Reduced Net Loss, Extends Cash Runway, Completes Share Repurchase, and Appoints New CEO

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$12.37
Mkt Cap
$794.455M
52W Low
$5.9
52W High
$18.93
52W Position info
110% above low
Off High info
35% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

ARVN has more than doubled off its 52-week low of $5.9 on elevated volume (1.9× avg).

Summary

Arvinas, Inc. filed its annual 10-K report, revealing a substantial reduction in net loss for 2025, an extended cash runway into the second half of 2028, and the completion of a $91.9 million share repurchase program. The company also announced the appointment of Randy Teel, Ph.D. as its new President and CEO, effective February 12, 2026.


Key Events · Earnings and Guidance · ARVN

  • Strong Financial Performance

    Net loss significantly reduced to $80.8 million in 2025 from $198.9 million in 2024, demonstrating improved operational efficiency.

  • Extended Cash Runway

    The company's cash, cash equivalents, and marketable securities of $685.4 million as of December 31, 2025, are projected to fund operations into the second half of 2028.

  • Completed Share Repurchase Program

    Arvinas completed its $100.0 million share repurchase program, acquiring 10,009,758 shares for an aggregate of $91.9 million, and has suspended further repurchases.

  • New President and CEO Appointed

    Randy Teel, Ph.D., previously Chief Business Officer, has been appointed President and CEO, effective February 12, 2026, succeeding John Houston, Ph.D., who remains a director and consultant.


Analysis · ARVN · Life Sciences

Arvinas's annual report highlights a substantial improvement in financial health, with a significant reduction in net loss and an extended cash runway, indicating enhanced operational efficiency and prudent financial management. The completion of a $91.9 million share repurchase program signals strong confidence from management and a commitment to returning capital to shareholders. The appointment of Randy Teel, Ph.D., an internal candidate, as the new President and CEO, following a planned transition, suggests leadership stability. While the NDA for vepdegestrant is progressing with a PDUFA date set, the strategic decision to outsource its commercialization reflects a pragmatic approach to resource allocation and risk management, allowing the company to focus on its core R&D. Continued advancement across multiple pipeline programs, including upcoming data readouts and trial initiations, underpins a positive outlook for future value creation.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARVN was trading at $12.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $794.5M. The 52-week trading range was $5.90 to $18.93. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARVN - Latest Insights

ARVN
Nov 03, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.09
Real-time Price: $6.91 info
Change: -$0.180 (-3%) info
Market Cap: $452.501M info
ARVN
Nov 03, 2026, 8:09 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.06
Real-time Price: $6.91 info
Change: -$0.150 (-2%) info
Market Cap: $452.501M info
ARVN
Nov 03, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $6.91 info
Change: -$0.610 (-8%) info
Market Cap: $452.501M info
ARVN
Oct 07, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $6.91 info
Change: -$0.610 (-8%) info
Market Cap: $452.501M info
ARVN
Sep 28, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.60
Real-time Price: $6.91 info
Change: -$0.690 (-9%) info
Market Cap: $452.501M info